Adeno-associated virus as a powerful tool for gene therapy

© 2025 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )

Download PDF

Cite

XML

Conflict of interest

Ling Yin is the Guest Editor of this special issue. The author declared that he has no known competing financial interests or personal relationships that could have influenced the work reported in this paper.

References

Tang R, Xu Z. Gene therapy: A double-edged sword with great powers. Mol Cell Biochem. 2020;474(1-2):73-81. doi: 10.1007/s11010-020-03834-3

Rind DM. The FDA and gene therapy for duchenne muscular dystrophy. JAMA. 2024;331(20):1705-1706. doi: 10.1001/jama.2024.5613

Singh A, Irfan H, Fatima E, Nazir Z, Verma A, Akilimali A. Revolutionary breakthrough: FDA approves CASGEVY, the first CRISPR/cas9 gene therapy for sickle cell disease. Ann Med Surg (Lond). 2024;86(8):4555-4559. doi: 10.1097/MS9.0000000000002146

Anguela XM, High KA. Hemophilia b and gene therapy: A new chapter with etranacogene dezaparvovec. Blood Adv. 2024;8(7):1796-1803. doi: 10.1182/bloodadvances.2023010511

Gardin A, Ronzitti G. Current limitations of gene therapy for rare pediatric diseases: Lessons learned from clinical experience with AAV vectors. Arch Pediatr. 2023;30(8S1):8S46-8S52. doi: 10.1016/S0929-693X(23)00227-0

Naso MF, Tomkowicz B, Perry WL 3^rd, Strohl WR. Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs. 2017;31(4):317-334. doi: 10.1007/s40259-017-0234-5

Asaad W, Volos P, Maksimov D, et al. AAV genome modification for efficient AAV production. Heliyon. 2023;9(4):e15071. doi: 10.1016/j.heliyon.2023.e15071

Tan F, Dong Y, Qi J, Yu W, Chai R. Artificial intelligence-based approaches for AAV vector engineering. Adv Sci (Weinh). 2025;12(9):e2411062. doi: 10.1002/advs.202411062

Maguire AM, Bennett J, Aleman EM, Leroy BP, Aleman TS. Clinical perspective: Treating rpe65-associated retinal dystrophy. Mol Ther. 2021;29(2):442-463. doi: 10.1016/j.ymthe.2020.11.029

Alsalloum A, Gornostal E, Mingaleva N, et al. A comparative analysis of models for AAV-mediated gene therapy for inherited retinal diseases. Cells. 2024;13(20):1706. doi: 10.3390/cells13201706

Pierce EA, Bennett J. The status of RPE65 gene therapy trials: Safety and efficacy. Cold Spring Harb Perspect Med. 2015;5:a017285. doi: 10.1101/cshperspect.a017285

Ogbonmide T, Rathore R, Rangrej SB, et al. Gene therapy for spinal muscular atrophy (SMA): A review of current challenges and safety considerations for onasemnogene abeparvovec (Zolgensma). Cureus. 2023;15(3):e36197. doi: 10.7759/cureus.36197

Yang H, Qing K, Keeler GD, et al. Enhanced transduction of human hematopoietic stem cells by AAV6 vectors: Implications in gene therapy and genome editing. Mol Ther Nucleic Acids. 2020;20:451-458. doi: 10.1016/j.omtn.2020.03.009

Yin L, Keeler GD, Zhang Y, et al. AAV3-mirna vectors for growth suppression of human hepatocellular carcinoma cells in vitro and human liver tumors in a murine xenograft model in vivo. Gene Ther. 2021;28:422-434. doi: 10.1038/s41434-020-0140-1

Zhu P, Dyka F, Ma X, et al. Disease mechanisms of x-linked cone dystrophy caused by missense mutations in the red and green cone opsins. FASEB J. 2021;35(10):e21927. doi: 10.1096/fj.202101066R

Glazkova DV, Bogoslovskaya EV, Urusov FA, et al. Generation of sars-cov-2 mouse model by transient expression of the human ace2 gene mediated by intranasal administration of aav-hace2. Mol Biol (Mosk). 2022;56:705-712. doi: 10.1134/S0026893322050065

Previous article in this issue

Next article in this issue

Global Translational Medicine, Electronic ISSN: 2811-0021 Print ISSN: 3060-8600, Published by AccScience Publishing